Clinical Trials
6 trialsNCT01998035 2024-08-22
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT01947140 2022-11-23
PDX+Romi
Columbia University
Phase 1/2 Completed
NCT01897012 2019-01-28
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT02281279 2016-08-11
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Withdrawn
NCT00079443 2013-07-01
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00042822 2011-05-17
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed